Literature DB >> 21741935

Regulator of calcineurin 1 (Rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.

Yong Jun Yang1, Adam J Macneil, Robert Junkins, Svetlana O Carrigan, Jin-Tian Tang, Nicholas Forward, David Hoskin, Jason N Berman, Tong-Jun Lin.   

Abstract

The presence of eosinophils in the lung is often regarded as a defining feature of asthma. On allergen stimulation, numbers of eosinophils and their progenitors are increased in both the bone marrow and lungs. Eosinophil progenitors provide an ongoing supply of mature eosinophils. Here, we report that deficiency in the regulator of calcineurin 1 gene (Rcan1) leads to a near-complete absence of eosinophilia in ovalbumin-induced allergic asthma in mice. In the absence of Rcan1, bone marrow cells produce significantly fewer eosinophils in vivo and in vitro on interleukin-5 stimulation. Importantly, eosinophil progenitor populations are significantly reduced in both naïve and ovalbumin-challenged Rcan1(-/-) mice. Bone marrow cells from Rcan1(-/-) mice are capable of developing into fully mature eosinophils, suggesting that Rcan1 is required for eosinophil progenitor production but may not be necessary for eosinophil maturation. Thus, Rcan1 represents a novel contributor in the development of eosinophilia in allergic asthma through regulation of eosinophil progenitor production.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741935      PMCID: PMC3157212          DOI: 10.1016/j.ajpath.2011.05.022

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  A critical role for eosinophils in allergic airways remodeling.

Authors:  Alison A Humbles; Clare M Lloyd; Sarah J McMillan; Daniel S Friend; Georgina Xanthou; Erin E McKenna; Sorina Ghiran; Norma P Gerard; Channing Yu; Stuart H Orkin; Craig Gerard
Journal:  Science       Date:  2004-09-17       Impact factor: 47.728

2.  Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene.

Authors:  J J Fuentes; M A Pritchard; X Estivill
Journal:  Genomics       Date:  1997-09-15       Impact factor: 5.736

3.  Incidence of bronchial asthma in Down syndrome.

Authors:  G L Forni; A Rasore-Quartino; M S Acutis; P Strigini
Journal:  J Pediatr       Date:  1990-03       Impact factor: 4.406

4.  Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress.

Authors:  D R Crawford; K P Leahy; N Abramova; L Lan; Y Wang; K J Davies
Journal:  Arch Biochem Biophys       Date:  1997-06-01       Impact factor: 4.013

Review 5.  Mechanism of airway inflammation in asthma.

Authors:  W W Busse; W F Calhoun; J D Sedgwick
Journal:  Am Rev Respir Dis       Date:  1993-06

Review 6.  The role of adhesion molecules in human eosinophil and basophil recruitment.

Authors:  B S Bochner; R P Schleimer
Journal:  J Allergy Clin Immunol       Date:  1994-09       Impact factor: 10.793

7.  Eosinophilic inflammation in asthma.

Authors:  J Bousquet; P Chanez; J Y Lacoste; G Barnéon; N Ghavanian; I Enander; P Venge; S Ahlstedt; J Simony-Lafontaine; P Godard
Journal:  N Engl J Med       Date:  1990-10-11       Impact factor: 91.245

8.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors:  M J Leckie; A ten Brinke; J Khan; Z Diamant; B J O'Connor; C M Walls; A K Mathur; H C Cowley; K F Chung; R Djukanovic; T T Hansel; S T Holgate; P J Sterk; P J Barnes
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

9.  A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart.

Authors:  J J Fuentes; M A Pritchard; A M Planas; A Bosch; I Ferrer; X Estivill
Journal:  Hum Mol Genet       Date:  1995-10       Impact factor: 6.150

Review 10.  Hypereosinophilic syndrome in a trisomy 21 fetus.

Authors:  Y Kusanagi; H Ochi; K Matsubara; M Ito
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

View more
  6 in total

1.  The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10.

Authors:  U Jain; T M Woodruff; A W Stadnyk
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Alok Kumar Verma; Anil Mishra
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

3.  Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis.

Authors:  Thibault Griseri; Isabelle C Arnold; Claire Pearson; Thomas Krausgruber; Chris Schiering; Fanny Franchini; Julie Schulthess; Brent S McKenzie; Paul R Crocker; Fiona Powrie
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

4.  Regulator of Calcineurin 1 in Periodontal Disease.

Authors:  Ulrike Peters; Eleni Solominidou; Yüksel Korkmaz; Stefan Rüttermann; Astrid Klocke; Thomas Frank Flemmig; Thomas Beikler
Journal:  Mediators Inflamm       Date:  2016-06-15       Impact factor: 4.711

5.  Cynanchi atrati and Its Phenolic Constituent Sinapic Acid Target Regulator of Calcineurin 1 (RCAN1) to Control Skin Inflammation.

Authors:  Seon Sook Kim; Nam Kyoung Kim; Su Ryeon Seo
Journal:  Antioxidants (Basel)       Date:  2022-01-21

6.  Endothelial Regulator of Calcineurin 1 Promotes Barrier Integrity and Modulates Histamine-Induced Barrier Dysfunction in Anaphylaxis.

Authors:  Constanza Ballesteros-Martinez; Nerea Mendez-Barbero; Alma Montalvo-Yuste; Bettina M Jensen; Aída Gomez-Cardenosa; Lotte Klitfod; María Garrido-Arandia; Gloria Alvarez-Llamas; Carlos Pastor-Vargas; Fernando Vivanco; Lene Heise Garvey; Javier Cuesta-Herranz; Lars K Poulsen; Vanesa Esteban
Journal:  Front Immunol       Date:  2017-10-20       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.